Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharmaceutical Industries Share Price Live Updates: Filing Of Application For Reclassification With Stock Exchanges
Sun Pharma Q4 PAT jumps 26% YoY to Rs 2,714 cr
Sun Pharmaceutical Industries has reported 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago.
Sun Pharmaceutical Industries consolidated net profit rises 26.24% in the March 2026 quarter
Sales rise 13.61% to Rs 14559.75 crore
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 19 May 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 19 May 2026 - Sun Pharmaceutical Industries, BSE and PB Fintech shares.
Five Stocks To Buy: BSE, Infosys, ICICI Bank And More | May 19, 2026
Top picks include financial market infrastructure major BSE, IT giants Infosys and Coforge, pharmaceutical major Sun Pharma, and private sector lender ICICI Bank.
Selling at higher levels turns 23,800 into key barrier for Nifty: Analysts
Benchmark Nifty closed lower last week. Analysts anticipate continued range-bound trading for Nifty this week. Trading strategies suggest buying on dips and selling on rallies within the 23,800-23,200 range. Specific stock recommendations include Indus Towers, Samvardhana Motherson International, Aditya Birla Capital, Sun Pharmaceutical Industries, and Arvind Limited. Investors are advised to consider these opportunities.
Sun Pharmaceutical receives credit ratings from CRISIL and ICRA
Sun Pharmaceutical Industries (Sun Pharma) announced that CRISIL has reaffirmed the rating of the company's long term bank facilities at CRISIL AAA and short term bank facilities and commercial paper at CRISIL A1+.
Sun Pharma gets relief in trademark case from High Court
The Bombay High Court has ruled in favour of Sun Pharmaceutical Industries. The court has restrained United Biotech from using a similar trademark. Sun Pharma's 'Octride' mark is protected. The dispute involves drugs for acromegaly and carcinoid tumours. The court found Sun Pharma had a stronger claim. This decision protects Sun Pharma's reputation and goodwill.
Indian Industry Celebrates $20.5 Billion Investment In US; Announce $1.1 Billion Projects
Indian pharmaceutical companies announced plans to invest more than $19.1 billion in the United States, anchored by Sun Pharmaceutical's planned $11.75 billion acquisition of New Jersey-based Organon & Co.
Sun Pharma explores funding mix for $12 billion Organon deal
Global lenders are exploring various financing options for Sun Pharmaceutical Industries' proposed $12 billion acquisition of Organon & Co. The Indian drugmaker is considering swapping Organon bondholders into Sun Pharma debt and a potential euro-denominated bond. Additionally, Sun Pharma plans to raise $3 billion to $4 billion in offshore loans, with deal approvals anticipated by December.
High Court relief to Sun Pharma, Ahd Co barred from using 'Esiraft'
Sun Pharmaceutical Industries has received a significant legal victory. The Bombay High Court has stopped Meghmani Lifesciences from using its product mark 'Esiraft'. This decision comes after Sun Pharma alleged trademark infringement and passing off rights concerning its brand 'Raciraft'. The court found the marks visually and phonetically similar, likely to cause confusion among consumers.
Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?
Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & Co. Investors remain cautious as the pharma major nears its biggest-ever overseas acquisition amid debt concerns and volatile global conditions.